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Abstract. Objectives: To determine the risk of cough- 
ing as an adverse reaction to ACE inhibitors under 
everyday circumstances in a large population, and to 
study whether this adverse ffect was duration or dose 
dependent. 
Design: A population-based case-control study. 
Setting: Ten general practices of 14 Dutch general prac- 
titioners (GP), in which all consultations, morbidity 
and medical interventions, including drugs prescribed, 
were registered over the 18 month period from 1st 
September, 1992 to 1st March, 1994. 
Subjects: 1458 patients with incident coughing and up 
to four controls per case were obtained (total 4182 con- 
trols), matched for GR All cases and controls were 20 
years or older and had no record of respiratory infec- 
tion, influenza, tuberculosis, asthma, chronic bronchi- 
tis, emphysema, congestive heart failure, sinusitis, 
laryngitis, haemoptysis or respiratory neoplasms dur- 
ing the study period. 
Results: Cases were 2.1-times more likely than controls 
to have been exposed to ACE inhibitors (95% CI 
1.5-3.1), but after adjustment the odds ratio was 1.4 
(95% CI 0.9-2.1). The crude odds ratio for captopril 
was 1.3 (95% CI 0.7-2.5), for enalapril 2.6 (95% CI 
1.6-4.2) and for lisinopril 2.0 (95% CI 0.5-9.3). The 
adjusted odds ratio for captopril was 0.9 (95% CI 
0.4 1.7), for enalapril 1.7 (95% CI 1.03-2.8) and for 
lisinopril 1.7 (95% CI 0.4-7.9). For patients who had 
been on ACE inhibitor treatment for no longer than 2 
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months the odds ratio was 4.8 (95% CI 1.7 13.3). The 
odds ratio declined to 2.0 (95% CI 1.1 3.8) for those 
who had taken an ACE inhibitor for 2-6 months, and 
to 1.6 (95% CI 0.9-2.7) for those on ACE-inhibitors 
for more than 6 months. 
Conclusion: The risk of coughing was increased twofold 
among ACE inhibitor users, but the odds ratios were 
no longer significant after controlling for several con- 
founding factors. The risk of developing cough due to 
ACE-inhibitors declines with the duration of treatment, 
possibly due to depletion of susceptible persons. 
Key words ACE inhibitors; cough, epidemiological 
study, general practice 
Introduction 
Coughing due to angiotensin converting enzyme (ACE) 
inhibitors was first reported more than 10 years ago in 
association with captopril [1, 2]. Other ACE-inhibitors 
were subsequently shown to increase the risk of cough- 
ing. Several mechanisms have been postulated for ACE 
inhibitor-induced cough, including for instance, 
increased bronchial reactivity, enhanced cough reflex, 
prostaglandin-, and bradykinin-mediated ffects and 
stimulation of pulmonary C-fibre receptors by elevated 
levels of substance P [3]. Several risk factors have been 
suggested, for instance, dose, duration of treatment, age 
and type of ACE-inhibitor, and coughing seems to be 
relatively more frequent in women [4 21]. The latter is 
in line with an earlier case-control study by the authors, 
in which the risk of coughing was higher in females 
than in males [22]. 
The reported frequency of cough due to ACE 
inhibitors has varied widely depending on the popula- 
tion under study and the methodological pproach 
used. Two large-scale postmarketing studies of unse- 
lected patient populations yielded much lower estimates 
of the incidence than studies in hospital or tertiary clin- 
ics [23, 24]. In some studies, the frequency of cough to 
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ACE inhibitors has been expressed as an incidence rate, 
whereas in others cumulative incidences and prevalence 
estimates have been used. It has been suggested that 
the risk of coughing may be higher with ACE-inhibitors 
with a long duration of action [3]. In an earlier study 
with another data base, we found a higher risk of 
coughing due to enalapril than to captopril [22]. As the 
study period was limited to 3 months, however, we were 
not able to examine any duration-effect relationship. 
The main aims of the current study were to obtain 
a risk estimate of coughing due to ACE inhibitors 
under everyday circumstances, in a large population 
over a longer period, and to examine whether the effect 
was dependent on dosage and duration of therapy. 
Subjects and methods 
Data source 
Data for the study came from the project for Integrated Primary 
Care Information (IPCI), a collaboration between the Department 
of Medical Informatics of the Erasmus University Medical School 
Rotterdam (MIEUR) and the Institute for Medical Statistics in the 
Hague. One of the purposes of IPCI is to conduct postmarketing 
surveillance studies using data from computer-based patient records 
of general practitioners (GPs). In 1992, 58% of Dutch GPs had 
installed an information system and 38 % had purchased and imple- 
mented a patient-record module [25]. Initially, only users of the 
ELIAS information system have participated in the project, but 
other systems will be included later. At MIEUR, the data are entered 
into a relational database management system. 
The events recorded include administrative data about all reg- 
istered patients and summaries of every visit of a patient o a GP: 
details of patient complaints, laboratory and other tests and their 
results, diagnoses, referrals to other health care providers and med- 
ical interventions, including prescribed rugs. For coding the rea- 
son for the encounter and the diagnoses, ELIAS supports the 
International Classification of Primary Care (ICPC) [26]. Of the 
recorded diagnoses, 73% had a diagnostic ICPC code, and the 
remainder were registered in free text. A database of all drugs 
available in the Netherlands, maintained by the Royal Dutch 
Association for the Advancement of Pharmacy, enables the coding 
of prescriptions, according to the Anatomical Therapeutic Chemical 
(ATC) classification scheme recommended by the World Health 
Organisation [27]. The data used for the study were collected from 
10 general practices in the period from 1st September, 1992 to 1st 
March, 1994. These 10 practices were considered to be representa- 
tive of GP standards, prescription profile and morbidity. 
Design and case definition 
In order to determine the risk of coughing as an adverse reaction 
to ACE inhibitors, we conducted a case-control study. Patients aged 
20 years and older, who consulted a GP for cough (ICPC code R05, 
or diagnosis 'cough' recorded in free text) for the first time during 
the study period (incident cases), were potentially eligible as case 
patients. For case patients who had two or more incident episodes 
of coughing during the study period, only the first episode was con- 
sidered. Four controls per case were randomly selected from patients 
who had had at least one consultation with the same GP office as 
the case during the study period, and who had not reported cough- 
ing during that period. Cases and controls were excluded if any of 
the following diseases were registered: respiratory infections, 
influenza tuberculosis, asthma, chronic bronchitis, emphysema, 
congestive heart failure, sinusitis, laryngitis, haemoptysis, respira- 
tory neoplasms, or other conditions known to cause or predispose 
to coughing. 
Data analysis 
The date of the first consultation for coughing of the case was taken 
as the index date and was assigned to each control to ensure that 
the period of possible exposure to the drug of interest was identi- 
cal in cases and controls, and to control for seasonal variation in 
morbidity and prescriptions. Cases and matched controls had 
exactly the same length of medical history prior to the index date. 
All control subjects had to have had at least one consultation after 
the index date of the case to ensure that they were alive and were 
still present in the catchment area. 
For each prescription of an ACE inhibitor a treatment course 
was calculated from the number of prescribed tablets divided by 
the prescribed number of tablets per day. If a subject was no longer 
on ACE inhibitor treatment, he length of the last treatment course 
was multiplied by the factor 1.1 with a minimum of 2 days and a 
maximum of 14 days in order to control for carry-over of drug 
effects. The total exposure xperience of each subject was calculated 
by summarising the duration of all treatment courses. Subjects were 
defined as users if the index date fell between the start and stop 
data of the particular ACE-inhibitor. 
The odds ratio of exposure to ACE inhibitors amongst patients 
with cough compared to control patients was calculated as the crude 
matched odds ratio and the 95% confidence interval (95% CI). For 
each potential risk factor a crude matched exposure odds ratio was 
calculated. The following variables were considered as potential 
confounders : age, gender, number of prescriptions, number of con- 
sultations, smoking status and use of NSAID, fi-blockers [28], thi- 
azides [29] or calcium-antagonists [30]. Treatment courses of these 
drugs were calculated as described above for ACE-inhibitors. 
Factors that caused a change in the crude odds ratio of use of ACE 
inhibitors of at least 5 % were included in the multivariate model, 
applying conditional logistic regression [31] with the EGRET sta- 
tistical package [32]. Subanalyses were performed for users of cap- 
topril, enalapril, lisinopril and perindopril, as well as for females 
and males, by applying the same multivariate models. We also inves- 
tigated whether this side effect was dose-dependent, using the same 
conditional model with 3 dose levels. For captopril and enalapril, 
but not as yet for other ACE inhibitors, there were sufficient data 
to evaluate risk according to dose. The effect of duration of expo- 
sure was also studied using the same multivariate model. 
Results 
In total, 44787 patients were registered in the 10 gen- 
eral practices. Of them, a total of 33779 patients had 
291145 consultations with their GR During the 18 
months of the study, the GPs wrote a total of 253880 
prescriptions. There was a total of 652 patients in the 
database who had been prescribed an ACE inhibitor or 
a combination with an ACE inhibitor on one or more 
occasions. 242 had been prescribed captopril or a com- 
bination with captopril (37%), 394 enalapril or a com- 
bination (60 %), 29 lisinopril or a combination (4 %) and 
31 perindopril (5%). Of the 652 patients given pre- 
scription for an ACE inhibitor, 181 reported coughing 
during the study period (27.8 %, 95 % CI 24.4%- 32.2 %). 
In the remainder of the population (n=33779-652= 
33127) coughing was reported by 5875 patients (17.7%; 
95% CI 17.3%-18.1%). 
Table 1 Comparison of 1458 
patients with cough and 4182 
controls matched by general 
practice 
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Cases Controls OR (95% CI) or 
(n = 1458) (n = 4182) P-value 
Mean age (SD) 
Females (%) 
Mean no. prescriptions 
Mean no. consultations 










50.2 (18.2) 46.8 (18.0) < 0.001 
903 (62) 2572 (62) 1.0 (0.9-1.2) 
15.1 9.9 < 0.001 
15.2 11.0 < 0.001 
48 (3.3%) 69 (1.6%) 2.1 (1.5-3.1) 
13 (0.9%) 29 (0_7%) 1.3 (0.72.5) 
30 (2.1%) 36 (0.9%) 2.6 (1.6-4.2) 
3 (0.2%) 4 (0.i%) 2.0 (0.5-9.3) 
2 (o.1%) o - 
410 (28%) 917 (22%) 1.4 (1.2-1.6) 
110 (7.5%) 246 (5.9%) 1.4 (1.1-1.7) 
15 (1.0%) 23 (0.5%) 2.0 (1,1-3.9) 
87 (6.0%) 124 (3.0%) 2.2 (1,6-2.9) 
20 (1.4%) 49 (i.2%) 1.2 (0.7-2.0) 
Number (%) of patients exposed on the index date 
In total, 6056 patients had coughing as the diagno- 
sis or for whom coughing was recorded in free text. 
4499 (74.3 %) of these observations were excluded from 
the analysis for the following reasons: age younger than 
20 years (35%), being a non-incident case (36.9%), 
suffering from one or more of the aforementioned con- 
ditions predisposing tocough (37.3 %). In principle four 
controls per case were selected for the remaining 1557 
observations. For 99 case patients no control could be 
found and they were excluded from further analysis. 
Hence, 1458 case patients comprised the study popu- 
lation. Of the 5832 identified control subjects, 1650 
(28.3%) were excluded because - age younger than 
20 y (17.9%), no consultation after the index date of 
the matching case (1.8%), and registration of one or 
more of the aforementioned conditions predisposing to
coughing (9.5%). Consequently, the final series con- 
sisted of4182 control subjects, comprising 2-3 matched 
controls for every case. 
A comparison of cases and controls is tabulated in 
Table 1. Several differences emerged which could 
explain differences in exposure frequency between cases 
and control subjects, irrespective of a real association 
between ACE inhibitors and cough. The cases were 
somewhat older than the controls, although the gen- 
der distribution was similar in the two groups. Cases 
received significantly more prescriptions and had more 
consultations per person during the study period than 
the control group. Patients with cough were more likely 
to be taking NSAID, fi-adrenoceptor blockers, thi- 
azides and calcium-antagonists. The percentage of 
smokers was not significantly different between cases 
and controls, but the figures were lower than expected. 
Factors were included in the model to study their effect 
upon the crude estimate. 
Of the cases 48 (3.3%) were identified as users of 
ACE inhibitors, against 69 (l.6%) of the controls. The 
results of the conditional logistic regression anaIyses 
without (crude) and with (adjusted) simultaneous con- 
trol for confounding variables are presented in Table 2. 
Cases were 2.l-times more likely than controls to have 
Table 2 Crude and adjusted odds ratios for exposure to ACE 
inhibitors. Exposure odds ratios with a value of unity outside the 
95%-confidence interval are printed in bold type 
Crude OR Adjusted OR 
All ACE inhibitors 2.1 (1.5-3.1) 1.4 (0.9-2.1) 
Captopril 1.3 (0.7-2.5) 0.9 (0.4-1.7) 
Enalapril 2.6 (1.6-4.2) 1.7 (1.03-2.8) 
Lismopril 2.0 (0.5-9.3) 1.7 (0.4~7.9) 
Perindopril - - 
Females 2.1 (1.3-3.5) 1.4 (0.8-2.5) 
Males 2.8 (1.2-6.6) 2.5 (1,0~6.3) 
Exposure < 2 months 4.8 (1.%13.3) 3.0 (1.05-8.3) 
Exposure 2-6 months 2.0 (1.1-3.8) 1.2 (0.6 2.3) 
Exposure > 6 months 1.6 (0.9-2.7) 1.0 (0.6-1.8) 
been exposed to ACE inhibitors (95 % CI 1.5-3.1), but 
after adjustment the odds ratio declined to 1.4 (95% 
CI 0.9 2.1). When results were analysed according to 
the specific ACE inhibitor used, a crude odds ratio of 
1.3 (95% CI 0.7-2.5) was found for captopriI, which 
declined to 0.9 (95% C1 0.4-1.7) after adjustment. For 
enalapril the crude odds ratio was 2.6 (95% CI 1.6-4.2) 
and 1.7 (95% CI 1.03-2.8) after adjustment. Patients 
with cough were 2.0-times (95 % CI 0.5-9.3) more likely 
than control patients to have been exposed to lisino- 
pril, and after adjustment the odds ratio was 1.7 (95% 
CI 0.4-7.9). Because there were no control patients 
exposed to perindopril, an odds ratio could not be cal- 
culated for this ACE inhibitor. 
Subanalyses according to sex yielded the following 
crude odds ratios: 2.1 (95% CI 1.3-3.5) and 2.8 (95% 
CI 1.2-6.6) for females and males, respectively. After 
adjustment neither value was significant. A dose- 
response relationship was not observed for captopril, 
or for enalapril. For captopril, the crude odds ratio 
increased from 0.8 (95% CI 0.2-3.7) in those treated 
with doses of 25 mg or less per day, and 1.2 (95% CI 
0.4-3.2) in those treated with more than 25 mg but less 
than 75 mg daily, to 2.1 (95% CI 0.8-5.6) for those 
patients treated with doses from 75-100 mg per day 
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(P---0.1). For enalapril, the crude odds ratio was 
2.0 (95% CI 0.7-5.8) in those treated with the lowest 
doses of 5mg or less per day, 2.9 (95% CI 1.1 7.8) 
in patients on 10-20 mg per day, and 2.7 for patients 
using the highest doses from 20-40mg per day; 
(P = 0.9). 
When overall results were stratified according to the 
duration of treatment, he odds ratios were 1.6 (95% 
CI 0.9-2.7) for long term users (> 6 months), 2.0 (95% 
CI 1.1 3.8) for patients who had been on ACE inhibitor 
treatment for 2 6 months and 4.8 (95% CI 1.7-13.3) 
for those just starting treatment (< 2 months). After 
adjustment, the figures declined and the only significant 
value was that for starters. 
Oiscussion 
It is very difficult to compare studies of the frequency 
of ACE inhibitor-induced cough in the literature. This 
is exemplified by the fact that is has been variously 
reported in 0.5 39% of recipients [3]. There are several 
reasons for this difficulty. First, the risk estimate isgiven 
as a straightforward frequency in some studies but as 
a point prevalence, period prevalence, incidence rate or 
cumulative incidence in others. Also, the length of the 
study period has varied. Second, while some studies 
have relied on spontaneous reporting, in others patients 
were specially asked about coughing. Third, several 
studies have comprised case series or small uncon- 
trolled studies with retrospective review of medical 
records, whereas the two largest studies so far were 
uncontrolled. Although there have also been some con- 
trolled studies, they have been small and not always 
representative of the use of ACE inhibitors under every- 
day circumstances. Fourth, the setting has differed from 
studies of patients hospitalised in tertiary clinics to data 
gathered in an outpatient setting. Fifth, none of the 
studies have controlled for the number of consultations 
per patient. For these reasons, we performed this case- 
control study in a large population under everyday cir- 
cumstances. 
Our crude results suggest that the risk of coughing 
is increased twofold among patients exposed to ACE 
inhibitors. But after controlling for confounding bias, 
the estimate did not remain statistically significantly 
away from the hull. Crude odd ratios were most 
influenced by the adjustments for number of consulta- 
tions, age and use of NSAID and calcium-antagonists. 
The fact that the cases were older and had more con- 
sultations per person, and might thus more easily have 
been recognised or diagnosed as coughers, explains part 
of their increased exposure to ACE inhibitors. 
Although it seems very unlikely that the crude increased 
risk can be explained solely by these factors, it shows 
why the number of consultations should be included 
in all studies of subjective adverse ffects based on GP 
data. The association appeared to be stronger with the 
longer-acting ACE inhibitors enalapril and lisinopril, 
but only with enalapril was the adjusted odds ratio still 
significant. Initially, it was postulated that coughing 
was probably related to the sulfhydryl group of capto= 
pril, but later studies suggested that cough occurred 
more frequently with enalapril, and postulated that it 
was related to its longer duration of action [3]. In our 
current study, we did not find evidence of a relation to 
gender, as has previously been suggested [4-22]. The 
risk of coughing was not increased in relation to the 
dose of captopril and enalapril. This finding is consis- 
tent with other reports [3, 22], although some scattered 
case reports have suggested that a reduction in dosage 
may sometimes decrease or even abolish cough. 
Although there were only sufficient data to permit a 
crude stratification by the duration of treatment, our 
results suggest a clear duration-effect relationship. 
According to the literature, cough induced by ACE 
inhibitors can occur from 24 hours to several months 
after initiation of therapy [33], and according to some 
papers no duration-effect relationship can be demon- 
strated [5, 6, 12, 34]. Analysis ofcaptopril and enalapril- 
induced cough revealed that the average time to onset 
was 9 and 4 weeks, respectively [5, 33]. Even with a 
variable latency period, however, it seems plausible that 
the chance that patients will develop coughing will con- 
sequently decline if they did not develop it during the 
first months of treatment. Discontinuation of ACE- 
inhibitors in patients with persistent coughing will con- 
sequently lead to a depletion of susceptible persons. 
Hence, diminution of the association with increasing 
duration of treatment seems a logical result. Duration 
of treatment might explain in part the large variation 
in risk estimates in the literature about the magnitude 
of this association. 
One of the advantages of a study using automated 
GP data is that information on disease and exposure 
are gathered by GPs who are not aware of the research 
hypothesis at the time of registration. Hence, no selec- 
tion of cases can be made by the GR Also, selection 
of control subjects was performed at random and was 
independent of drug use. It is possible, however, that 
selection bias may account for the slightly higher risk 
of coughing after enalapril than captopril in our study, 
if doctors were liable to try a newer ACE-inhibitor in 
patients who developed coughing to older ACE- 
inhibitors. It must be emphasised that not all patients 
will consult heir GP because of coughing, and so there 
might be underestimation f the risk if some of the 
controls had cough due to an ACE-inhibitor without 
consulting their GP. This does not seem to be very 
likely, however, for two reasons. First, to control for 
this potential bias, the control group consisted of 
patients who had had at least one consultation with 
their GP in the same period and second, as the dry 
tickling cough to ACE-inhibitors is burdensome and 
very persistent, controls would have presented them- 
selves to the GP sooner or later and would thus have 
been registered as cases. 
A major concern in a case-control study is possible 
information bias. Recall bias was not very likely to occur 
as the case-control study made use of data which had 
already been gathered before the onset of the disease. 
Another type of information bias might occur, however, 
if GPs were more likely to diagnose coughing in users 
of ACE inhibitors than in other patients. During regis- 
tration and classification of symptoms and diseases, 
cough is a well-known adverse effect of ACE inhibitor 
treatment, so it is possible that some selection in regis- 
tration might have occurred. Information bias could 
also be the result of patients who presented themselves 
to their GPs with coughing after reading the data sheet. 
A third point is the evaluation of misclassification of 
disease and exposure. As we were unable to confirm 
the relationship between coughing and use of captopril 
- the first ACE-inhibitor and probably the most well- 
known cause of coughing - such information bias is 
unlikely. Cough is a very general and poorly defined 
symptom. In fact, we were only interested in a partic- 
ular type of cough; the non-productive, tickling cough. 
For this type of subjective diagnosis, the International 
Classification of Primary Care is insufficiently subtle to 
describe the patient's condition. Cases of ACE inhibitor- 
induced cough may not have been recognized as such, 
and so could have been misclassified as acute respira- 
tory disease, bronchitis, asthma or deteriorating cardiac 
failure. As patients with such diagnoses were also 
excluded from the control group, this does not neces- 
sarily jeopardise valid estimation of the odds ratio. The 
criteria for defining exposure also require consideration. 
Subjects were only considered as exposed if the index 
date fell between the start and stop date of the total 
estimated exposure experience. Subjects who received a 
prescription for an ACE inhibitor outside the time 
frame between this index date and the beginning of the 
data collection period may have been misclassified as 
non-exposed. As the average period between coughing 
and the start of the study period was almost 10 months, 
however, such misclassification is unlikely. Subjects may 
also have been misclassified as non-exposed, if they 
received a prescription from an ACE inhibitor from a 
medical specialist, as such prescriptions were not regis- 
tered in the GP data base. Although GPs usually take 
over the treatment of such patients after one or several 
consultations, such misclassification might have led to 
a slight bias of the risk estimation towards the null 
hypothesis. Unfortunately, smoking habits are poorly 
registered in GP databases but in an earlier study 
we did not find a relationship between smoking and 
exposure to ACE-inhibitors [22]. 
In conclusion, we found that the risk for coughing 
due to ACE-inhibitors was highest in the first two 
months of exposure that it declined with duration of 
exposure. This could be explained by the assumption 
that susceptible persons were changed to other ther- 
apy. It is possible that such depletion of susceptibles 
may partly explain the lower risk in users of captopril 
than in patients on enalapril. 
443 
References 
1. HaveIka J, Vetter H, Studer A, Greminger P, Luscher T, 
Wollnik S, Siegenthaler W, Vetter W (1982) Acute and 
chronic effects of Angiotensin-Converting Enzyme Inhibitor 
Captopril in Severe Hypertension. Am J Cardiol 49: 
1467-1474 
2. Sesoko S, Kaneko Y (1985) Cough associated with the use of 
captopril. Arch Intern Med 145:1524 
3. Israili ZH, Hall WD (1992) Cough and angioneurotic edema 
associated with angiotensin-converting e zyme inhibitor ther- 
apy. A review of the literature and pathophysiology. Ann Intern 
Med 117:234-242 
4. Inman WHW (1986) Enalapril-induced cough. Lancet 2:1218 
5. Coulter DM, Edwards IR (1987) Cough associated with cap- 
topril and enalapril. BMJ 294:i521 1523 
6. Yeo WW, Ramsey LE (1990) Persistent dry cough with 
enalapril: incidence depends on method used. J Hum Hypertens 
4:517 520 
7. Stoller JK, Elghazawi A0 Mehta AC, Vidt DG (1988) Captopril- 
induced cough. Chest 93:659-661 
8. Webb D, Benjamin N, Collier J, Robinson B (1986) Enalapril- 
induced cough. Lancet 2:1094 
9. Kaufman J, Casanova JE, Riendl P, Schlueter DP (1989) 
Bronchial hyperreactivity and cough due to angiotensin-con- 
verting enzyme inhibltors. Chest 95:544-548 
10. Hume AL, Murphy JL, Lauerman SE (1989) Angiotensin-con- 
verting enzyme inhibitor-induced cough. Pharmacotherapy 9: 
88-90 
11. Morice AH, Brown MJ, Higenbottam T(1989) Cough 
Associated with Angiotensin Converting Enzyme Inhibition. J 
Cardiovasc Pharmacol 13 [Suppl 3] : $59 $62 
12. McEwan JR, Choudry N, Street R, Fuller RW (1989) Change 
in cough reflex after treatment with enalapril and ramipril. 
BMJ 299:i3-16 
13. Yeo WW, Foster G, Ramsay LE (1991) Prevalence of persis- 
tent cough during long-term enalapril treatment: controlled 
study versus nifedipine. Q J Med 80:763-770 
14. Poole MD, Postma DS (1991) Characterization of cough 
associated with angiotensin converting enzyme inhibitors 
Otolaryngol Head Neck Surg 105:714-716 
15. Yeo WW, Maclean D, Richardson PJ, Ramsey LE (1991) 
Cough and enalapril: assessment by spontaneous reporting and 
visual analogue scale under double-blind conditions. Br J Clin 
Pharmacol 31 : 356-359 
16. Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S 
(1992) Female sex as an important determinant of lisinopril- 
induced cough. Lancet 339:372 
17. Strocchi E, Valtancoli, G, Ambrosioni E (1989) The incidence 
of cough during treatment with angiotensin converting enzyme 
inhibitors. J Hypertens 7 [Suppl 6]:$308 $309 
18. Moore N, Noblet C, Joannides R, Ollagnier M, Imbs JL, Lagier 
G (1993) Cough and ACE inhibitors. Lancet 341:61 
19. Lefebvre J, Poirier L, Lacourciere Y (1992) Prospective trial on 
captropril-related cough. Ann Pharmacother 26:161 164 
20. Carre A, Vasmant D, Elmalem J, Thiery P (1991) Tolerability 
of ramipril in a multicenter study of mild-to-moderate hyper- 
tension in general practice. J Cardiovasc Pharmacol 18 [suppl 
2]:S141-S143 
21. Strocchi E, Valtancoli G, Ricci C, Malini PL, Bassein L, 
Ambrosioni E (1992) Postmarketing studies of subjective side 
effects; a case for strict methodological criteria and careful 
analysis of data. Pharmacol Res 25 [Suppl 1]: 79-80 
22. Visser LE, Stricker BHCh, Van der Velden J, Paes AHP, Bakker 
A (1995) ACE-inhibitor associated cough: a population-based 
case-control study. J Clin Epidemiol 48:851 857 
23. Inman WHW, Rawson NSB, Wilton LV, Pearce GL, Speirs CJ 
(1988) Postmarketing Surveillance of enalapril. 1: Results of 
Prescription Event-Monitoring. BMJ 297:286 289 
24. Cooper WD, Sheldon D, Brown D, Kimber GR, Isitt VL, 
Currie WJ (1987) Post-marketing surveillance of enalapril: 
444 
experience in 11,710 hypertensive patients in general practice. 
J R Coll Gen Pract 37:346-349 
25. Van der Lei J, Duisterhout JS, Westerhof HP, Van der Does 
E, Cromme PVM, Boon WM, Van Bemmel JH (1993) The 
introduction of computer-based patient records in the Nether- 
lands. Ann Int Med 119:1036 1041 
26. Lamberts H, Woods M (1987) International c assification of 
primary care. Oxford University Press, Oxford 
27. Anonymous. (1987) Anatommal therapeutic chemical (ATC) 
index: Including defined daily doses (DDD) for plain sub- 
stances. World Health Organization, Oslo 
28. Puolijoki H J, Nieminen MM, Siitonen LO, Lahdensuo AH, 
Reinikainen PM (1989) Is a simultaneous beta-blocker therapy 
a risk factor for enalapril-induced cough? Respiration 55: 
127 128 
29. Kamei J, Kasuya Y (1992) The effect of hydrochlorothiazide 
on the enhanced coughing associated with treatment with 
enalapril. Eur J Pharmacol 213:137-139 
30. Fogari R, Zoppi A, Tettamanti F, Malamani GD, Tinelli C, 
Salvetti A (1992) Effects of nifedipine and indomethacin on 
cough induced by angtiotensin converting enzyme inhibitors: a
double-blind radomized, cross-over study, J Cardiovasc 
Pharmacol 19 : 670-673 
31. Kleinbaum DG, Kupper LL, Muller KE (1988) Applied regres- 
sion analysis and other multivariate methods. PWS-Kent 
Publishing Company, Boston 
32. Egret. [] Statistics and Epidemiology Research Corporation, 
Seattle, WA. 
33. Just PM (1989) The positive association of cough with 
angiotensin-converting e zyme inhibitors. Pharmacotherapy 9 : 
82-87 
34. Sebastian JL, Mc Kinney WP, Kaufman J, Young MJ (1991) 
Angiotensin converting enzyme inhibitors and cough. Chest 
99 : 36-39 
